Your browser doesn't support javascript.
Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma.
Wiedmeier-Nutor, Julia E; Iqbal, Madiha; Rosenthal, Allison C; Bezerra, Evandro D; Garcia-Robledo, Juan Esteban; Bansal, Radhika; Johnston, Patrick B; Hathcock, Matthew; Larsen, Jeremy T; Bergsagel, P Leif; Wang, Yucai; Reeder, Craig B; Leis, Jose F; Fonseca, Rafael; Palmer, Jeanne M; Gysbers, Brianna J; Mwangi, Raphael; Warsame, Rahma M; Kourelis, Taxiarchis; Hayman, Suzanne R; Dingli, David; Kapoor, Prashant; Kumar, Shaji K; Durani, Urshila; Villasboas, Jose C; Paludo, Jonas; Bennani, N Nora; Nowakowski, Grzegorz; Ansell, Stephen M; Castro, Januario E; Kharfan-Dabaja, Mohamed A; Lin, Yi; Vergidis, Paschalis; Murthy, Hemant S; Munoz, Javier.
  • Wiedmeier-Nutor JE; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ. Electronic address: Wiedmeier.Julia@mayo.edu.
  • Iqbal M; Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL.
  • Rosenthal AC; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ.
  • Bezerra ED; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Garcia-Robledo JE; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ.
  • Bansal R; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Johnston PB; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Hathcock M; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Larsen JT; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ.
  • Bergsagel PL; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ.
  • Wang Y; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Reeder CB; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ.
  • Leis JF; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ.
  • Fonseca R; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ.
  • Palmer JM; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ.
  • Gysbers BJ; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
  • Mwangi R; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
  • Warsame RM; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Kourelis T; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Hayman SR; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Dingli D; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Kapoor P; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Kumar SK; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Durani U; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
  • Villasboas JC; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Paludo J; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Bennani NN; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Nowakowski G; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Ansell SM; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Castro JE; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ.
  • Kharfan-Dabaja MA; Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL.
  • Lin Y; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Vergidis P; Division of Hematology, Mayo Clinic, Rochester, MN.
  • Murthy HS; Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL.
  • Munoz J; Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ.
Clin Lymphoma Myeloma Leuk ; 23(6): 456-462, 2023 06.
Article in English | MEDLINE | ID: covidwho-2286674
ABSTRACT
COVID-19 adversely affects individuals with cancer. Several studies have found that seroconversion rates among patients with hematologic malignancies are suboptimal when compared to patients without cancer. Patients with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) are immunocompromised due to impaired humoral and cellular immunity in addition to prescribed immunosuppressive therapy. Chimeric antigen receptor T-cell (CAR T) therapy is now widely used for NHL and MM, but little is known about seroconversion rates after COVID-19 vaccination among these populations. We evaluated SARS-CoV-2 spike-binding IgG antibody levels following COVID-19 vaccination among NHL and MM CAR T therapy recipients. Out of 104 CAR T infusions, 19 patients developed known COVID-19 infection post-CAR T. We tested 17 patients that received CAR T for antibody spike titers post COVID-19 vaccination, only 29 % (n = 5) were able to mount a clinically relevant antibody response (>250 IU/mL).
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / Receptors, Chimeric Antigen / COVID-19 / Multiple Myeloma Type of study: Experimental Studies / Prognostic study Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: Clin Lymphoma Myeloma Leuk Journal subject: Neoplasms Year: 2023 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / Receptors, Chimeric Antigen / COVID-19 / Multiple Myeloma Type of study: Experimental Studies / Prognostic study Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: Clin Lymphoma Myeloma Leuk Journal subject: Neoplasms Year: 2023 Document Type: Article